白藜芦醇用于预防和治疗结直肠癌的研究进展

国际肿瘤学杂志››2016,Vol. 43››Issue (1): 67-70.doi:10.3760/cma.j.issn.1673-422X.2016.01.019

白藜芦醇用于预防和治疗结直肠癌的研究进展

徐家辉,刘德英,许志军,马文霞,张庆玲

510515 广州，南方医科大学第一临床医学院（徐家辉、刘德英、许志军），基础医学院病理学系（马文霞、张庆玲）；南方医科大学南方医院病理科（张庆玲）

收稿日期:2015-05-18出版日期:2016-01-08发布日期:2015-12-03
通讯作者:张庆玲 E-mail:zqllc8@126.com
基金资助:

国家自然科学基金（81272760、81472712）；广东省科技计划（c1221020700008）

Research progress of resveratrol on the prevention and treatment of colorectal cancer

Xu Jiahui, Liu Deying, Xu Zhijun, Ma Wenxia, Zhang Qingling

First School of Clinical Medicine, Southern Medical University, Guangzhou 510515, China

Received:2015-05-18Online:2016-01-08Published:2015-12-03
Contact:Zhang Qingling E-mail:zqllc8@126.com
Supported by:

National Natural Science Foundation of China (81272760, 81472712); Science and Technology Program of Guangdong Province of China (c1221020700008)

摘要/Abstract

摘要：近年来研究显示，白藜芦醇具有抗氧化、抗炎的特性，能够调节细胞内糖和神经酰胺的代谢，激活转录激活因子3和过氧化物酶体增殖物激活受体γ等抑癌因子，又可下调鼠类肉瘤病毒癌基因的表达，抑制癌细胞上皮间质转化的发生等，使得白藜芦醇在预防和治疗结直肠癌方面发挥重要作用。另外，白藜芦醇在联合治疗中显示出广阔的应用前景。

徐家辉,刘德英,许志军,马文霞,张庆玲. 白藜芦醇用于预防和治疗结直肠癌的研究进展[J]. 国际肿瘤学杂志, 2016, 43(1): 67-70.

Xu Jiahui, Liu Deying, Xu Zhijun, Ma Wenxia, Zhang Qingling. Research progress of resveratrol on the prevention and treatment of colorectal cancer[J]. Journal of International Oncology, 2016, 43(1): 67-70.

参考文献

［1］ Talero E, AvilaRoman J, Motilva V. Chemoprevention with phytonutrients and microalgae products in chronic inflammation and colon cancer［J］. Curr Pharm Des, 2012, 18(26): 3939-3965. ［2］ Park EJ, Pezzuto JM. The pharmacology of resveratrol in animals and humans［J］. Biochim Biophys Acta, 2015, 1852(6): 1071-1113. DOI:10.1016/j.bbadis.2015.01.014. ［3］季佳文, 周怀君. 白藜芦醇对肿瘤中微小RNA的调节作用［J］. 国际肿瘤学杂志, 2013, 40(8): 587-590. DOI:10.3760/cma.j.issn.1673422X.2013.08.009. ［4］倪琴, 周怀君. 白藜芦醇在妇科肿瘤中的研究进展［J］. 国际肿瘤学杂志, 2014, 41(7): 526-529. DOI:10.3760/cma.j.issn.1673422X.2014.07.014 ［5］ Pangeni R, Sahni JK, Ali J, et al. Resveratrol: review on therapeutic potential and recent advances in drug delivery［J］. Expert Opin Drug Deliv, 2014, 11(8): 1285-1298. DOI:10.1517/17425247.2014.919253. ［6］ Howells LM, Berry DP, Elliott PJ, et al. Phase Ⅰ randomized, doubleblind pilot study of micronized resveratrol (srt501) in patients with hepatic metastasessafety, pharmacokinetics, and pharmacodynamics［J］. Cancer Prev Res (Phila), 2011, 4(9): 14191425. DOI:10.1158/1940-6207.CAPR-11-0148. ［7］ Temraz S, Mukherji D, Shamseddine A. Potential targets for colorectal cancer prevention［J］. Int J Mol Sci, 2013, 14(9): 17279-17303. DOI:10.3390/ijms140917279. ［8］ Serra D, Rufino AT, Mendes AF, et al. Resveratrol modulates cytokineinduced Jak/STAT activation more efficiently than 5aminosalicylic acid: an in vitro approach［J］. PLoS One, 2014, 9(10): e109048. DOI:10.1371/journal.pone.0109048. ［9］ Sengottuvelan M, Deeptha K, Nalini N. Resveratrol ameliorates DNA damage, prooxidant and antioxidant imbalance in 1, 2dimethylhydrazine induced rat colon carcinogenesis［J］. Chem Biol Interact, 2009, 181(2): 193-201. DOI:10.1016/j.cbi.2009.06.004. ［10］ OlivoMarston SE, Hursting SD, Perkins SN, et al. Effects of calorie restriction and dietinduced obesity on murine colon carcinogenesis, growth and inflammatory factors, and microRNA expression［J］. PLoS One, 2014, 9(4): e94765. DOI:10.1371/journal.pone.0094765. ［11］ Fouad MA, Agha AM, Merzabani MM, et al. Resveratrol inhibits proliferation, angiogenesis and induces apoptosis in colon cancer cells: calorie restriction is the force to the cytotoxicity［J］. Hum Exp Toxicol, 2013, 32(10): 1067-1080. DOI:10.1177/0960327113475679. ［12］ Tsunoda T, Ota T, Fujimoto T, et al. Inhibition of phosphodiesterase4 (PDE4) activity triggers luminal apoptosis and AKT dephosphorylation in a 3D coloniccrypt model［J］. Mol Cancer, 2012, 11: 46. DOI:10.1186/1476-4598-11-46. ［13］ Tsunoda T, Ishikura S, Doi K, et al. Resveratrol induces luminal apoptosis of human colorectal cancer HCT116 cells in threedimensional culture［J］. Anticancer Res, 2014, 34(8): 4551-4555. ［14］ Saud SM, Li W, Morris NL, et al. Resveratrol prevents tumorigenesis in mouse model of Kras activated sporadic colorectal cancer by suppressing oncogenic Kras expression［J］. Carcinogenesis, 2014, 35(12): 2778-2786. DOI:10.1093/carcin/bgu209. ［15］ Park SJ, Ahmad F, Philp A, et al. Resveratrol ameliorates agingrelated metabolic phenotypes by inhibiting cAMP phosphodiesterases［J］. Cell, 2012, 148(3): 421-433. DOI:10.1016/j.cell.2012.01.017. ［16］ Aires V, Brassart B, Carlier A, et al. A role for peroxisome proliferatoractivated receptor gamma in resveratrolinduced colon cancer cell apoptosis［J］. Mol Nutr Food Res, 2014, 58(9): 17851794. DOI:10.1002/mnfr.201300962. ［17］ Galadari S, Rahman A, Pallichankandy S, et al. Tumor suppressive functions of ceramide: evidence and mechanisms［J］. Apoptosis, 2015, 20(5): 689711. DOI:10.1007/s10495-015-1109-1. ［18］ Ulrich S, Huwiler A, Loitsch S, et al. De novo ceramide biosynthesis is associated with resveratrolinduced inhibition of ornithine decarboxylase activity［J］. Biochem Pharmacol, 2007, 74(2): 281-289. DOI:10.1016/j.bcp.2007.04.001. ［19］ Shin KO, Park NY, Seo CH, et al. Inhibition of sphingolipid metabolism enhances resveratrol chemotherapy in human gastric cancer cells［J］. Biomol Ther (Seoul), 2012, 20(5): 470-476. DOI:10.4062/biomolther.2012.20.5.470. ［20］ Ji Q, Liu X, Han Z, et al. Resveratrol suppresses epithelialtomesenchymal transition in colorectal cancer through TGFβ1/Smads signaling pathway mediated Snail/Ecadherin expression［J］. BMC Cancer, 2015, 15: 97. DOI:10.1186/s12885-015-1119-y. ［21］ Ji Q, Liu X, Fu X, et al. Resveratrol inhibits invasion and metastasis of colorectal cancer cells via malat1 mediated Wnt/βcatenin signal pathway［J］. PLoS One, 2013, 8(11): e78700. DOI:10.1371/journal.pone.0078700. ［22］ Whitlock NC, Bahn JH, Lee SH, et al. Resveratrolinduced apoptosis is mediated by early growth response1, Krüppellike factor 4, and activating transcription factor 3［J］. Cancer Prev Res (Phila), 2011, 4(1): 116-127. DOI:10.1158/1940-6207.CAPR-10-0218. ［23］ Bottone FG Jr, AlstonMills B. The dietary compounds resveratrol and genistein induce activating transcription factor 3 while suppressing inhibitor of DNA binding/differentiation1［J］. J Med Food, 2011, 14(6): 584-593. DOI:10.1089/jmf.2010.0110. ［24］ Ali I, Braun DP. Resveratrol enhances mitomycin Cmediated suppression of human colorectal cancer cell proliferation by upregulation of p21WAF1/CIP1［J］. Anticancer Res, 2014, 34(10): 5439-5446. ［25］ Kaminski BM, Weigert A, Scherzberg MC, et al. Resveratrolinduced potentiation of the antitumor effects of oxaliplatin is accompanied by an altered cytokine profile of human monocytederived macrophages［J］. Apoptosis, 2014, 19(7): 1136-1147. DOI:10.1007/s10495-014-0988-x. ［26］ Osman AM, AlMalki HS, AlHarthi SE, et al. Modulatory role of resveratrol on cytotoxic activity of cisplatin, sensitization and modification of cisplatin resistance in colorectal cancer cells ［J］. Mol Med Rep, 2015, 12(1): 1368-1374. DOI:10.3892/mmr.2015.3513. ［27］ Nguyen AV, Martinez M, Stamos MJ, et al. Results of a phase Ⅰ pilot clinical trial examining the effect of plantderived resveratrol and grape powder on Wnt pathway target gene expression in colonic mucosa and colon cancer［J］. Cancer Manag Res, 2009, 1: 25-37. ［28］ Patel KR, Brown VA, Jones DJ, et al. Clinical pharmacology of resveratrol and its metabolites in colorectal cancer patients［J］. Cancer Res, 2010, 70(19): 7392-7399. DOI:10.1158/0008-5472.CAN-10-2027. ［29］ Chow HH, Garland LL, Hsu CH, et al. Resveratrol modulates drug and carcinogenmetabolizing enzymes in a healthy volunteer study［J］. Cancer Prev Res (Phila), 2010, 3(9): 1168-1175. DOI:10.1158/1940-6207.CAPR-09-0155.

[1]	张蕊, 褚衍六.基于FIT与肠道菌群的结直肠癌风险评估模型的研究进展[J]. 国际肿瘤学杂志, 2024, 51(6): 370-375.
[2]	高凡, 王萍, 杜超, 褚衍六.肠道菌群与结直肠癌非手术治疗的相关研究进展[J]. 国际肿瘤学杂志, 2024, 51(6): 376-381.
[3]	王俊毅, 洪楷彬, 纪荣佳, 陈大朝.癌结节对结直肠癌根治性切除术后肝转移的影响[J]. 国际肿瘤学杂志, 2024, 51(5): 280-285.
[4]	孙国宝, 杨倩, 庄庆春, 高斌斌, 孙晓刚, 宋伟, 沙丹.结直肠癌肝转移组织病理学生长方式研究进展[J]. 国际肿瘤学杂志, 2024, 51(2): 114-118.
[5]	刘德宝, 孙子雯, 鲁守堂, 徐海东.ASB6在结直肠癌组织中的表达及临床意义[J]. 国际肿瘤学杂志, 2023, 50(8): 470-474.
[6]	陈卓, 陶俊, 陈琳, 柯晶.外周血miR-194联合粪便miR-143检测对结直肠癌临床筛查的价值[J]. 国际肿瘤学杂志, 2023, 50(5): 268-273.
[7]	黄镇, 张蔡羽天, 柯少波, 石薇, 赵文思, 陈永顺.结直肠癌患者术后预后模型的构建[J]. 国际肿瘤学杂志, 2023, 50(3): 157-163.
[8]	徐良富, 李袁飞.MSS型结直肠癌肿瘤微环境及免疫联合治疗研究进展[J]. 国际肿瘤学杂志, 2023, 50(3): 186-190.
[9]	刘玉杰, 赵志强, 王子琤.早期结直肠癌患者外周血单个核细胞中TOP2A、ERBB2的水平及其诊断价值[J]. 国际肿瘤学杂志, 2023, 50(12): 717-722.
[10]	陶红, 殷红, 罗宏, 陶佳瑜.靶向肿瘤相关巨噬细胞增强结直肠癌免疫检查点抑制剂疗效的潜在策略[J]. 国际肿瘤学杂志, 2023, 50(11): 683-687.
[11]	王熙, 吴川清.结直肠癌多药耐药逆转的研究进展[J]. 国际肿瘤学杂志, 2023, 50(1): 42-46.
[12]	高一钊, 刘洋, 刘秋龙, 邢金良.循环游离核酸在结直肠癌临床诊疗中的应用[J]. 国际肿瘤学杂志, 2022, 49(9): 555-559.
[13]	何哲锋, 吴燚阳, 李振军, 应晓江.炎性相关标志物对结直肠癌的预测价值[J]. 国际肿瘤学杂志, 2022, 49(9): 560-563.
[14]	赵莹, 张革红.AGR、PLR及NLR变化与转移性结直肠癌化疗疗效的相关性研究[J]. 国际肿瘤学杂志, 2022, 49(8): 473-477.
[15]	黄梦盼, 王学红, 芦永福.FOXA2在结直肠癌中的作用机制及其在诊疗中的作用[J]. 国际肿瘤学杂志, 2022, 49(8): 490-493.